Skip to main contentSkip to navigation
Sirius Investors

DMYD-B.ST Stock: Diamyd Medical AB (publ) Stock Price, Analysis & Insights

Get live DMYD-B.ST stock price $1.15, comprehensive Diamyd Medical AB (publ) stock analysis, charts, news, and expert forecast. Real-time DMYD-B.ST stock data and investment insights.

1.15
0.17%Today
DMYD-B.STDiamyd Medical AB (publ) • Stockholm Stock Exchange • Healthcare
Market Cap
154.10M
Volume
512.32K
52W High
17.88
52W Low
0.90

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing ...

Company Information

CEO
Ulf Hannelius
Sector
Healthcare
Industry
Biotechnology
Employees
30

Contact Information

Address
Kungsgatan 29
Country
SE

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 2.29)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Diamyd Medical AB (publ) shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Diamyd Medical AB (publ)
  • Investors should consider how Diamyd Medical AB (publ) fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

154.10M

P/E Ratio (TTM)

-0.88

Beta

2.29

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.